[Ip-health] MSF urges PM Modi not to make any trade commitments toUS threatening access to medicines

leena menghaney leenamenghaney at gmail.com
Fri Sep 20 03:27:56 PDT 2019


MSF urges PM Modi not to make any trade commitments to US threatening
access to medicines

New Delhi, 19 September 2019 - Ahead of the Prime Minister Modi’s visit to
US to discuss a ‘trade-package’ with US President Donald Trump, Médecins
Sans Frontières/ Doctors Without Borders (MSF) urges the Indian government
to not make any commitments regarding intellectual property, as it will
impact millions of people who rely on affordable generic medicines produced
in India. India supplies affordable generic medicines to people and
governments worldwide, including to MSF’s medical humanitarian projects,
which are present in more than 60 countries.

The Indian Commerce Ministry and the United States Trade Representative
have been hammering out a trade package before the Indian Prime Minister’s
visit to the United States scheduled to start this Sunday.

The U.S. Trade Representative has a long history of throwing every single
intimidation and pressure tactic at the Indian government to undermine
price lowering competition from its manufacturers of medicines and other
medical products.

Already in the run up to the visit, news reports have indicated that US
pharmaceutical corporations backed by the US ambassador are pressuring the
Indian government to give up health safeguards like price control on
essential medical devices. This is deeply problematic precedent as it makes
India’s policy space susceptible to pressures from major pharmaceutical
corporations, who have sought to constantly undermine generic competition
in the past.

Quote by Leena Menghaney, Head- India & South Asia, MSF Access Campaign:

“India should be cautious while signing any trade package or launching
trade negotiations with the US that may include harmful provisions
threatening India’s ability to produce and supply affordable medical
products. Going by past practices, the key focus of the US in any trade
pact has always been to prioritise the interests of its pharmaceutical
corporations at the cost of people lives.

The world can’t afford to see India’s pharmacy shut down to protect the
profiteering of U.S. pharmaceutical corporations.”

-- 
Leena Menghaney
Mobile: 9811365412


More information about the Ip-health mailing list